ArticleJournal of clinical microbiology1996
Strain variation among and antifungal susceptibilities of isolates of Candida krusei.
Article in Journal of clinical microbiology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Raman Spectroscopy of OralInternational journal of molecular sciences · 2022Article
- Development of a Multiplex PCR Short Tandem Repeat Typing Scheme for Candida krusei.Journal of clinical microbiology · 2022Article
- Experimental methodologies and evaluations of computer-aided drug design methodologies applied to a series of 2-aminothiophene derivatives with antifungal activities.Molecules (Basel, Switzerland) · 2012Article
- Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.Journal of clinical microbiology · 2008Article
- Comparison of PCR- and HinfI restriction endonuclease-based methods for typing of Candida krusei isolates.Journal of clinical microbiology · 2004Article
- The Candida dubliniensis CdCDR1 gene is not essential for fluconazole resistance.Antimicrobial agents and chemotherapy · 2002Article
- Prospective study of Candida species in patients at a comprehensive cancer center.Antimicrobial agents and chemotherapy · 2001Article
- Electrophoretic karyotyping of Candida albicans strains isolated from premature infants and hospital personnel in a neonatal intensive care unit.Folia microbiologica · 2001Article
- Candidaemia in cancer patients and in children in a neonatal intensive care unit.Folia microbiologica · 2001Article
- Emerging Issues in Nosocomial Fungal Infections.Current infectious disease reports · 1999Article
- Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital.Journal of clinical microbiology · 1999Article
- Identification of Candida species by randomly amplified polymorphic DNA fingerprinting of colony lysates.Journal of clinical microbiology · 1997Article
- Rapid identification and fingerprinting of Candida krusei by PCR-based amplification of the species-specific repetitive polymorphic sequence CKRS-1.Journal of clinical microbiology · 1997Article
- Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro.Antimicrobial agents and chemotherapy · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida krusei is an emerging pathogen that is well known for its propensity to develop resistance to fluconazole and other azoles. Despite the potential clinical significance of C. krusei, little is known of its epidemiology and genetic diversity as defined by the newer DNA-based typing methods. We investigated the genotypic diversity and antifungal susceptibility of 67 clinical isolates from 44 patients and 5 health care workers from six different medical centers. Strain delineation was performed by restriction endonuclease analysis of genomic DNA (REAG) with the restriction enzyme HinfI followed by conventional electrophoresis. The susceptibility of the isolates to the antifungal agents amphotericin B, flucytosine, fluconazole, and itraconazole was determined by methods recommended by the National Committee for Clinical Laboratory Standards. The MICs at which 90% of the isolates were inhibited ranged from 1.0 microgram/ml for itraconazole to 64 micrograms/ml for fluconazole. In general, isolates from a given patient, or epidemiologically related isolates from a single institution, were identical by molecular typing methods. Epidemiologically unrelated isolates were distinctly different by the REAG typing method employed. These data document the genetic diversity and antifungal susceptibility of clinical isolates of C. krusei.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.